Roche: Most Of Avastin Business In Europe Is Now Gone

Follows Competition From Biosimilar Bevacizumab Since Last Summer

 
• By Dean Rudge

Several biosimilars to Roche’s Avastin are now available in Europe following market formation in June last year, adding to Roche’s woes for its legacy oncology drugs, including MabThera/Rituxan and Herceptin.

Roche_White_Logo
Amgen and Pfizer were the first moves on biosimilar Avastin in the EU • Source: Shutterstock

More from Biosimilars

More from Products